[Progress in medical treatment of heart failure].
Heart failure is one of the most important diseases in the recent years. Because of the advances in the cardiological practice, it can be identified frequently knowing much better pathophysiological mechanism and the investigation of different drugs for the improvement in symptomatology and the functional class of this patients. The first step is taking care about the diet, which it has to be sodium free, a restrictive about intake. The second step is the use of diuretics and digitalis that has been used for many years. About the new treatment in the medical therapy is the point that we analyze in the present work and we think that in the future this alternatives will be much better and incorporated to the basic therapeutics.
López Mora
E
E
Departamento de Terapia Intensiva Posquirúrgica, Instituto Nacional de Cardiología Ignacio Chávez, INCICH, Juan Badiano No. 1, 14080 México, D.F.
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002120:Calcium Channel Agonists / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D002316:Cardiotonic Agents / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D004232:Diuretics / Q000627:therapeutic use; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D010726:Phosphodiesterase Inhibitors / Q000627:therapeutic use; D011480:Protease Inhibitors / Q000627:therapeutic use; D013963:Thyroid Hormones / Q000627:therapeutic use
D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002120:Calcium Channel Agonists; D002121:Calcium Channel Blockers; D002316:Cardiotonic Agents; D004232:Diuretics; D010726:Phosphodiesterase Inhibitors; D011480:Protease Inhibitors; D013963:Thyroid Hormones; D004077:Digoxin